Ashley Elsensohn

Dr. Ashley Elsensohn


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn
JHJosiah Hanson
Josiah Hanson
TFTammie C Ferringer
Tammie C Ferringer

30 November 2022 in Dermatopathology
Verified
Journal Article
Open access
PDF file
APAriel Park
Ariel Park
LWLulu Wong
Lulu Wong
ALAnnalise Lang
Annalise Lang
CKChristina Kraus
Christina Kraus
NANancy Anderson
Nancy Anderson
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn
Dupilumab is a humanized IgG4 monoclonal-antibody that is approved by the United States Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older. In recent years, several case studies have associated the unmasking or progression of cutaneous T-cell lymphomas (CTCL) with dupilumab treatment. To date, all reported cases of dupilumab-associated CTCL have shown a CD4+ T-helper-cell-predominant immunophenotype. Here, we report a case of a 72-year-old man who presented with a 2-year history of a diffuse, pruritic eruption, who was started on dupilumab for 9 weeks. He subsequently developed mycosis fungoides (MF) with a CD8+-predominant immunophenotype. Overall, cases of CD8+ mycosis fungoides are less common and relatively less understood than their CD4+ counterparts, with varied presentations and courses. We present a case of dupilumab-associated CD8+ MF to highlight this presentation for pathologists and providers.

16 February 2023 in Dermatopathology
Verified
Journal Article
Open access
PDF file
Marina Kristy IbraheimMarina Kristy Ibraheim
Marina Kristy Ibraheim
RGRohit Gupta
Rohit Gupta
JGJerad M. Gardner
Jerad M. Gardner
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn
In recent years, researchers have explored potential uses for artificial intelligence (AI) in medical practice

18 February 2024 in JAAD Case Reports
Verified
Journal Article
Open access
KLKalisa Lum
Kalisa Lum
RSRuth Sanchez
Ruth Sanchez
CZCici Zhou
Cici Zhou
SSSophia Sangar
Sophia Sangar
HDHarry Dao
Harry Dao
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn

1 December 2023 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
ISIsabella Sanchez
Isabella Sanchez
MIMarina K. Ibraheim
Marina K. Ibraheim
BLBonnie A. Lee
Bonnie A. Lee
CKChristina N. Kraus
Christina N. Kraus
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn
The presence or absence of tissue eosinophilia has previously aided in the diagnosis of inflammatory skin conditions. However, recent studies have elucidated the presence of eosinophils in traditionally eosinophil-poor inflammatory skin diseases, such as dermatomyositis (DM), psoriasis, and lichen sclerosus (LS). This systematic review of the literature explores previous studies of tissue eosinophilia in skin biopsies of dermatoses that are believed to be classically poor in eosinophil. We identified 26 studies, the majority of which were retrospective reviews. The percent of specimens with increased eosinophils in psoriasis ranged from 18%–73%, pityriasis rubra pilaris (PRP) 22%–63%, LS 29%–53%, DM 15%–44%, morphea 8%–45%, hypertrophic lichen planus (LP) 0%–21%, and oral LP 0%–4%. These reports of tissue eosinophilia in reputed eosinophil-poor dermatologic conditions present a diagnostic pitfall and suggest that tissue eosinophilia itself should not be used to rule out a diagnosis of one of these conditions.

10 January 2023 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
KKKatherine Kim
Katherine Kim
MDMansee Desai
Mansee Desai
Ashley ElsensohnAshley Elsensohn
Ashley Elsensohn
CKChristina N. Kraus
Christina N. Kraus